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RifampinObjective background: Mycobacterium simiae has been identified as the most prevalent slow
growing mycobacteria that has been isolated among Iranian patients. Due to an impor-
tance of molecular approaches in the treatment of nontuberculosis mycobacteria, this
study aimed to evaluate molecular drug susceptibility testing against the first-line (rifam-
pin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in
different subtypes of M. simiae.
Methods: The study involved all patients presenting to our referral tuberculosis center from
March 2014 to August 2016, with confirmation of M. Simiae. For all sputum samples, after
digestion and decontamination, followed by DNA extraction, polymerase chain reaction-
restriction fragment length polymorphism was performed using the hsp65 gene. Further-
more, susceptibility to rifampin, isoniazid, ciprofloxacin, amikacin, and kanamycin were
evaluated using rpoB, inhA, katG, gyrA, and rrs genes, respectively.
Results: In total, 60 cases (58.33% men and 41.66% women) of M. simiae infections were
identified and all were confirmed as subtype I. All the patients were resistant to the first
line-tuberculosis drugs, while 88.33% and 91.66% of cases were susceptible to ciprofloxacin
and both amikacin and kanamycin, respectively.
Conclusion: Regarding the given result, first-line tuberculosis drugs should be excluded
from the treatment regimen of M. simiae patients. In addition, subtype I seems to be the
most or even the only isolated M. simiae subtype among all Iranian patients. While both
amikacin and kanamycin drugs showed better efficacy in the treatmentM. simiae, the most
susceptible antibiotic is still indeterminate.Conflicts of interest
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